Examining Teva and Bayer's Generics Battle

The German pharmaceutical company Bayer has filed a US lawsuit against Israeli rival Teva for false advertising and patent infringement, Bayer said late on Tuesday.Bayer says that Teva "falsely claims" on the label of its Gianvi product that the treatement "contains the same product stabilizer as YAZ," a best-selling oral contraceptive made by the German group.The lawsuit was filed in the Northern District of Illinois "for false advertising and patent infringement," a Bayer statement said.

By The Value Investor: Shares of Conceptus (CPTS) rose 19.5% in Monday's trading session. The developer and marketer of the flagship Essure permanent birth control procedure reported its first quarter results for 2013.

By Mark Bern

EP Vantage submits:At the beginning of 2010, Teva (TEVA) announced hugely ambitious sales growth targets that signalled the acquisitive company had no intention of slowing down (Teva's bullish forecast enhances generics outlook, January 8, 2010).

Over the past few years, the focus of the entire health care industry has been on the Affordable Care Act. The law has had, and will continue to have, huge effects on hospitals, doctors, and pharmaceutical companies. 

By Freedonia Freelance: The so-called patent-cliff is a two edged sword. Mainly, it's a cliff for big pharmaceutical companies that make branded products to fall off whenever the patents on their branded drugs expire. That's when generic drug makers like Watson (WPI) swoop in with generic products that undercut the brand names with lower prices.

The German chemical and pharmaceutical company Bayer faces a US lawsuit on behalf of a teenager who died from a blood clot allegedly linked to its YAZ contraceptive.Michelle Pfleger, an 18-year-old college student in North Carolina, died of cardiac arrest last September after taking YAZ, also known as Yasmin or Ocella, to treat acne, according to the complaint filed on Tuesday."One day she was a freshman at college so full of hope and promise and the next she was gone," Pfleger's mother, Joan Cummins said.

Watson Pharmaceuticals (WPI) Q1 2011 Earnings Call April 27, 2011 8:30 am ET Executives Patricia Eisenhaur - Vice President of Investor Relations & Corporate Communications R. Joyce - Chief Financial Officer, Principal Accounting Officer, Executive Vice President, Corporate Controller and Treasurer Paul Bisaro - Chief Executive Officer, President and Director